ARD-101 (ARCE Therapeutics)

N/A

Report date: 2025/01/26 15:06:18

Base Information

Drug NameARD-101 (ARCE Therapeutics)

Drug Alias NameCAR T-cell therapy DashCAR (ARCE Therapeutics)

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyBiologics > Protein drugs > Recombinant protein > Fusion protein

Mechanisms of ActionImmunostimulantsT lymphocytes stimulants

TargetsUpdating

Therapy Area/IndicationsLymphoma, B-Cell

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryTaiwan

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesARCE Therapeutics Inc

China Registration ClassN/A

Develop Information

Active CompaniesARCE Therapeutics Inc

Inactive CompaniesN/A

Active IndicationsLymphoma, B-Cell

Inactive IndicationsN/A

Other Information

ATC CodeN/A